{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:49:29Z","timestamp":1781070569150,"version":"3.54.1"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":455,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2024,7,17]],"date-time":"2024-07-17T00:00:00Z","timestamp":1721174400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,12,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Transthyretin cardiac amyloidosis (ATTR-CM) may be an underestimated cause of heart failure among geriatric patients and represent a unique phenotype and prognostic profile.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and results<\/jats:title>\n                    <jats:p>This retrospective, observational, cohort study characterizes cardiac and extracardiac disorders at diagnosis and assesses prognosis among ATTR-CM patients based on age (geriatric vs. non-geriatric) and amyloidosis subtype (wild type, ATTRwt and hereditary, ATTRv). In total, 943 patients with ATTR-CM were included, of which 306 had ATTRv and 637 had ATTRwt. Among these, 331 (35.1%) were non-geriatric (&amp;lt;75 years), and 612 (64.9%) were geriatric (\u226575 years). The population exhibited conduction abnormalities, atrial fibrillation and ischaemic heart disease that progressively deteriorated with age. Among ATTRwt patients, peripheral neuropathy, neurovegetative symptoms, and hearing loss were present across all age groups, but reports of carpal tunnel symptoms or surgery decreased with age. Conversely, among ATTRv patients, reports of extracardiac symptoms increased with age and Val122ILe mutation was highly prevalent among geriatric patients. The 3-year survival was higher among non-geriatric ATTR-CM patients (76%) than geriatric patients (55%) and predictors of 3-year mortality differed. Notably, predictors identified among geriatric patients were alkaline phosphatase (ALP) (HR = 1.004, 95% CI: [0.001\u20131.100)], troponin T hs (HR = 1.005, 95% CI: [1.001\u20131.120)] and tricuspid insufficiency (HR = 1.194, 95% CI: [1.02\u20131.230)]. Whereas, among non-geriatric patients, NT-proBNP (HR = 1.002, 95% CI: [1.02\u20131.04], global longitudinal strain (HR = 0.95, 95% CI: [0.922\u20130.989], and glomerular filtration rate (HR = 0.984, 95% CI: [0.968\u20131.00) were identified. We propose a 3-stage prognostic staging system combining troponin T hs (\u226544 ng\/L) and ALP levels (\u2265119 UI\/L). In the geriatric population, this model discriminated survival more precisely than the National Amyloidosis Centre staging, particularly for classifying between stage 1 (82%), stage 2 (50%) and stage 3 (32%) for ATTRv and ATTRwt.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These diagnostic and prognostic indicators, along with ATTR subtype, highlight the distinct characteristics of this important, geriatric ATTR-CM patient group. Recognizing these mortality markers can be valuable for geriatricians to improve the prognostic quality management of geriatric patients with ATTR-CM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ehf2.14793","type":"journal-article","created":{"date-parts":[[2024,7,18]],"date-time":"2024-07-18T01:41:04Z","timestamp":1721266864000},"page":"3814-3832","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Phenotype and Prognostic Factors in Geriatric and Non-Geriatric Patients with Transthyretin Cardiomyopathy"],"prefix":"10.1093","volume":"11","author":[{"given":"Eugenia","family":"Volpentesta","sequence":"first","affiliation":[{"name":"Departement of Geriatrics, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri-Mondor\/Albert-Chenevier Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Departement of Geriatrics, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Charles Foix Hospital , Ivry-sur-seine ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mounira","family":"Kharoubi","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"GRC Amyloid Research Institute, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"DHU A-TVB, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristiano","family":"Donadio","sequence":"additional","affiliation":[{"name":"Departement of Geriatrics, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Charles Foix Hospital , Ivry-sur-seine ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kahina","family":"Rebiai","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascale","family":"Fanen","sequence":"additional","affiliation":[{"name":"Department of Genetics, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Funalot","sequence":"additional","affiliation":[{"name":"GRC Amyloid Research Institute, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Department of Genetics, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thierry","family":"Gendre","sequence":"additional","affiliation":[{"name":"Department of Neurology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB), University Paris Est Cr\u00e9teil , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"Audard","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB), University Paris Est Cr\u00e9teil , Cr\u00e9teil ,","place":["France"]},{"name":"Department of Nephrology and Renal Transplantation, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Canoui-Poitrine","sequence":"additional","affiliation":[{"name":"DHU A-TVB, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health , Cr\u00e9teil ,","place":["France"]},{"name":"Department of Public Health Department, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Itti","sequence":"additional","affiliation":[{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB), University Paris Est Cr\u00e9teil , Cr\u00e9teil ,","place":["France"]},{"name":"Department of Nuclear Medicine, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Clinical Investigation Center 1430, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuel","family":"Teiger","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"GRC Amyloid Research Institute, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"DHU A-TVB, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Violaine","family":"Plant\u00e9-Bordeneuve","sequence":"additional","affiliation":[{"name":"Department of Neurology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale (INSERM) U955, Institut Mondor de Recherche Biom\u00e9dicale (IMRB), University Paris Est Cr\u00e9teil , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Oghina","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Tixier","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Mallet","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amaury","family":"Broussier","sequence":"additional","affiliation":[{"name":"Clinical Epidemiology and Ageing (CEpiA) Geriatrics, Primary Care and Public Health , Cr\u00e9teil ,","place":["France"]},{"name":"Department of Geriatrics, AP-HP, Hopitaux Henri-Mondor\/Emile Roux , Limeil-Brevannes ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4058-3848","authenticated-orcid":false,"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"GRC Amyloid Research Institute, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira","family":"Zaroui","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), DMU Care, Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"Cardiac Amyloidosis Referral Centre, Cardiogen Network, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]},{"name":"GRC Amyloid Research Institute, AP-HP (Assistance Publique-H\u00f4pitaux de Paris), Henri Mondor University Hospital , Cr\u00e9teil ,","place":["France"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,7,17]]},"reference":[{"key":"2026012113124941000_ehf214793-bib-0001","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1093\/eurheartj\/ehz173","article-title":"Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the transthyretin amyloidosis outcomes survey (THAOS)","volume":"43","author":"Damy","year":"2019","journal-title":"Eur Heart J"},{"key":"2026012113124941000_ehf214793-bib-0002","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1111\/joim.12585","article-title":"One mutation, two distinct disease variants: unravelling the impact of transthyretin amyloid fibril composition","volume":"281","author":"Suhr","year":"2017","journal-title":"J Intern Med"},{"key":"2026012113124941000_ehf214793-bib-0003","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1007\/s00415-019-09688-0","article-title":"Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy","volume":"268","author":"Adams","year":"2021","journal-title":"J Neurol"},{"key":"2026012113124941000_ehf214793-bib-0004","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1185\/03007995.2012.754348","article-title":"THAOS - The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis","volume":"29","author":"Coelho","year":"2013","journal-title":"Curr Med Res Opin"},{"key":"2026012113124941000_ehf214793-bib-0005","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.jacc.2016.06.033","article-title":"Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system","volume":"68","author":"Grogan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2026012113124941000_ehf214793-bib-0006","doi-asserted-by":"publisher","DOI":"10.1161\/circheartfailure.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer","year":"2019","journal-title":"Circ Heart Fail"},{"key":"2026012113124941000_ehf214793-bib-0007","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/13506129.2017.1374946","article-title":"Safety and efficacy of a TTR specific antisense oligonucleotide in patients with transthyretin amyloid cardiomyopathy","volume":"24","author":"Benson","year":"2017","journal-title":"Amyloid"},{"key":"2026012113124941000_ehf214793-bib-0008","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1093\/eurheartj\/ehx043","article-title":"Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths","volume":"38","author":"Gonz\u00e1lez-L\u00f3pez","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012113124941000_ehf214793-bib-0009","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1161\/circulationaha.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"2026012113124941000_ehf214793-bib-0010","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonz\u00e1lez-L\u00f3pez","year":"2015","journal-title":"Eur Heart J"},{"key":"2026012113124941000_ehf214793-bib-0011","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"2026012113124941000_ehf214793-bib-0012","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2021.749523","article-title":"Incidence and characterization of concealed cardiac amyloidosis among unselected elderly patients undergoing post-mortem examination","volume":"8","author":"Porcari","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"2026012113124941000_ehf214793-bib-0013","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1161\/CIRCULATIONAHA.118.038169","article-title":"Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis","volume":"140","author":"Lane","year":"2019","journal-title":"Circulation"},{"key":"2026012113124941000_ehf214793-bib-0014","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/j.anclin.2019.04.007","article-title":"Geriatric pharmacology: an update","volume":"37","author":"Andres","year":"2019","journal-title":"Anesthesiol Clin"},{"key":"2026012113124941000_ehf214793-bib-0015","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fcvm.2023.1124660","article-title":"Amylo-AFFECT-QOL, a self-reported questionnaire to assess health-related quality of life and to determine the prognosis in cardiac amyloidosis","volume":"10","author":"Kharoubi","year":"2023","journal-title":"Front Cardiovas Med"},{"key":"2026012113124941000_ehf214793-bib-0016","doi-asserted-by":"publisher","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"2026012113124941000_ehf214793-bib-0017","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","article-title":"Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy","volume":"379","author":"Maurer","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012113124941000_ehf214793-bib-0018","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N Engl J Med"},{"key":"2026012113124941000_ehf214793-bib-0019","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1080\/13506129.2019.1685487","article-title":"Inotersen therapy of transthyretin amyloid cardiomyopathy","volume":"27","author":"Dasgupta","year":"2020","journal-title":"Amyloid"},{"key":"2026012113124941000_ehf214793-bib-0020","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia","year":"2021","journal-title":"Eur Heart J"},{"key":"2026012113124941000_ehf214793-bib-0021","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/S0140-6736(20)32332-1","article-title":"Efficacy and safety of lowering LDL cholesterol in older patients: a systematic review and meta-analysis of randomised controlled trials","volume":"396","author":"Gencer","year":"2020","journal-title":"Lancet"},{"key":"2026012113124941000_ehf214793-bib-0022","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n461","article-title":"Age dependent associations of risk factors with heart failure: pooled population based cohort study","volume":"372","author":"Tromp","year":"2021","journal-title":"BMJ"},{"key":"2026012113124941000_ehf214793-bib-0023","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.echo.2017.01.007","article-title":"Recommendations for noninvasive evaluation of native valvular regurgitation: a report from the American Society of Echocardiography developed in collaboration with the Society for Cardiovascular Magnetic Resonance","volume":"30","author":"Zoghbi","year":"2017","journal-title":"J Am Soc Echocardiogr"},{"key":"2026012113124941000_ehf214793-bib-0024","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1001\/jamacardio.2022.1781","article-title":"A simple score to identify increased risk of transthyretin amyloid cardiomyopathy in heart failure with preserved ejection fraction","volume":"7","author":"Davies","year":"2022","journal-title":"JAMA Cardiol"},{"key":"2026012113124941000_ehf214793-bib-0025","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cardfail.2016.10.008","article-title":"Transthyretin cardiac amyloidosis in older Americans","volume":"22","author":"Brunjes","year":"2016","journal-title":"J Card Fail"},{"key":"2026012113124941000_ehf214793-bib-0026","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1080\/13506129.2019.1620724","article-title":"Atrial fibrillation and subtype of atrial fibrillation in cardiac amyloidosis: clinical and echocardiographic features, impact on mortality","volume":"26","author":"Sanchis","year":"2019","journal-title":"Amyloid"},{"key":"2026012113124941000_ehf214793-bib-0027","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.jacep.2020.04.020","article-title":"Cardiac implantable electronic devices: a window into the evolution of conduction disease in cardiac amyloidosis","volume":"6","author":"Rehorn","year":"2020","journal-title":"JACC Clin Electrophysiol"},{"key":"2026012113124941000_ehf214793-bib-0028","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1002\/ejhf.2532","article-title":"Redefining the epidemiology of cardiac amyloidosis. A systematic review and meta-analysis of screening studies","volume":"24","author":"Aimo","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113124941000_ehf214793-bib-0029","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/jcm10153415","article-title":"Frailty in wild-type transthyretin cardiac amyloidosis: the tip of the iceberg","volume":"10","author":"Broussier","year":"2021","journal-title":"J Clin Med"},{"key":"2026012113124941000_ehf214793-bib-0030","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1080\/13506129.2017.1330744","article-title":"How your ears can tell what is hidden in your heart: wild-type transthyretin amyloidosis as potential cause of sensorineural hearing loss in elderly-AmyloDEAFNESS pilot study","volume":"24","author":"B\u00e9quignon","year":"2017","journal-title":"Amyloid"},{"key":"2026012113124941000_ehf214793-bib-0031","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1002\/ejhf.2776","article-title":"Prevalence, characteristics and outcomes of older patients with hereditary versus wild-type transthyretin amyloid cardiomyopathy","volume":"25","author":"Porcari","year":"2023","journal-title":"Eur J Heart Fail"},{"key":"2026012113124941000_ehf214793-bib-0032","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1002\/ejhf.2606","article-title":"Progression of echocardiographic parameters and prognosis in transthyretin cardiac amyloidosis","volume":"24","author":"Chacko","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113124941000_ehf214793-bib-0033","doi-asserted-by":"publisher","first-page":"1677","DOI":"10.1002\/ejhf.2589","article-title":"Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis","volume":"24","author":"Antonopoulos","year":"2022","journal-title":"Eur J Heart Fail"},{"key":"2026012113124941000_ehf214793-bib-0034","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1002\/ehf2.13093","article-title":"Impact of tricuspid regurgitation on survival in patients with cardiac amyloidosis","volume":"8","author":"Fagot","year":"2021","journal-title":"ESC Heart Fail"},{"key":"2026012113124941000_ehf214793-bib-0035","doi-asserted-by":"publisher","first-page":"2879","DOI":"10.1093\/eurheartj\/ehx350","article-title":"Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement","volume":"38","author":"Casta\u00f1o","year":"2017","journal-title":"Eur Heart J"},{"key":"2026012113124941000_ehf214793-bib-0036","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1093\/eurheartj\/suab107","article-title":"Transthyretin amyloidosis in aortic stenosis: clinical and therapeutic implications","volume":"23","author":"Fabbri","year":"2021","journal-title":"Eur Heart J Suppl"},{"key":"2026012113124941000_ehf214793-bib-0037","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1016\/j.jcmg.2019.10.011","article-title":"Multiparametric echocardiography scores for the diagnosis of cardiac amyloidosis","volume":"13","author":"Boldrini","year":"2020","journal-title":"JACC Cardiovasc Imaging"},{"key":"2026012113124941000_ehf214793-bib-0038","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1080\/13506129.2018.1556156","article-title":"Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations","volume":"26","author":"Concei\u00e7\u00e3o","year":"2019","journal-title":"Amyloid"},{"key":"2026012113124941000_ehf214793-bib-0039","doi-asserted-by":"publisher","first-page":"S43","DOI":"10.1016\/j.amjcard.2022.09.011","article-title":"Counseling family members and monitoring for evidence of disease in asymptomatic carriers of amyloid transthyretin cardiac amyloidosis","volume":"185","author":"Barker","year":"2022","journal-title":"Am J Cardiol"},{"key":"2026012113124941000_ehf214793-bib-0040","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1146\/annurev.med.51.1.543","article-title":"The genetics of the amyloidoses","volume":"51","author":"Buxbaum","year":"2000","journal-title":"Annu Rev Med"},{"key":"2026012113124941000_ehf214793-bib-0041","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1002\/ejhf.2658","article-title":"Frequency of hereditary transthyretin amyloidosis among elderly patients with transthyretin cardiomyopathy","volume":"24","author":"Maestro-Benedicto","year":"2022","journal-title":"Eur J Heart Fail"}],"container-title":["ESC Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3814\/64517018\/eschf_11_6_3814.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eschf\/article-pdf\/11\/6\/3814\/64517018\/eschf_11_6_3814.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T18:14:50Z","timestamp":1769019290000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eschf\/article\/11\/6\/3814\/8269419"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,17]]},"references-count":41,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,7,17]]},"published-print":{"date-parts":[[2024,12,1]]}},"URL":"https:\/\/doi.org\/10.1002\/ehf2.14793","relation":{},"ISSN":["2055-5822"],"issn-type":[{"value":"2055-5822","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,12]]},"published":{"date-parts":[[2024,7,17]]},"assertion":[{"value":"2023-06-21","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-03-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-07-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}